# Phase Analysis and Obstructive CAD on Rubidium PET

> **NCT01840696** · PHASE2 · WITHDRAWN · sponsor: **Emory University**

## Conditions studied

- Coronary Artery Disease

## Interventions

- **DRUG:** Regadenoson

## Key facts

- **NCT ID:** NCT01840696
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2013-10
- **Primary completion:** 2014-05
- **Final completion:** 2014-05
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** PI leaving facility
- **Last updated:** 2014-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01840696

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01840696, "Phase Analysis and Obstructive CAD on Rubidium PET". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01840696. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*